Show simple item record

dc.contributor.authorBilen, MA
dc.contributor.authorRini, BI
dc.contributor.authorVoss, MH
dc.contributor.authorLarkin, J
dc.contributor.authorHaanen, JBAG
dc.contributor.authorAlbiges, L
dc.contributor.authorPagliaro, LC
dc.contributor.authorVoog, EG
dc.contributor.authorLam, ET
dc.contributor.authorKislov, N
dc.contributor.authorMcGregor, BA
dc.contributor.authorLalani, A-KA
dc.contributor.authorHuang, B
dc.contributor.authordi Pietro, A
dc.contributor.authorKrulewicz, S
dc.contributor.authorRobbins, PB
dc.contributor.authorChoueiri, TK
dc.coverage.spatialUnited States
dc.date.accessioned2022-08-22T10:47:51Z
dc.date.available2022-08-22T10:47:51Z
dc.date.issued2022-02-15
dc.identifier1078-0432.CCR-21-1688
dc.identifier.citationClinical Cancer Research, 2022, 28 (4), pp. 738 - 747
dc.identifier.issn1078-0432
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/5287
dc.identifier.eissn1557-3265
dc.identifier.eissn1557-3265
dc.identifier.doi10.1158/1078-0432.CCR-21-1688
dc.description.abstractPURPOSE: To evaluate the association between neutrophil-to-lymphocyte ratio (NLR) and efficacy of avelumab plus axitinib or sunitinib. EXPERIMENTAL DESIGN: Adult patients with untreated advanced renal cell carcinoma (RCC) with a clear-cell component, ≥1 measurable lesions, Eastern Cooperative Oncology Group performance status of 0 or 1, fresh or archival tumor specimen, and adequate renal, cardiac, and hepatic function were included. Retrospective analyses of the association between baseline NLR and progression-free survival (PFS) and overall survival (OS) in the avelumab plus axitinib or sunitinib arms were performed using the first interim analysis of the phase 3 JAVELIN Renal 101 trial (NCT02684006). Multivariate Cox regression analyses of PFS and OS were conducted. Translational data were assessed to elucidate the underlying biology associated with differences in NLR. RESULTS: Patients with below-median NLR had longer observed PFS with avelumab plus axitinib [stratified HR, 0.85; 95% confidence interval (CI), 0.634-1.153] or sunitinib (HR, 0.56; 95% CI, 0.415-0.745). In the avelumab plus axitinib or sunitinib arms, respectively, median PFS was 13.8 and 11.2 months in patients with below-median NLR, and 13.3 and 5.6 months in patients with median-or-higher NLR. Below-median NLR was also associated with longer observed OS in the avelumab plus axitinib (HR, 0.51; 95% CI, 0.300-0.871) and sunitinib arms (HR, 0.30; 95% CI, 0.174-0.511). Tumor analyses showed an association between NLR and key biological characteristics, suggesting a role of NLR in underlying mechanisms influencing clinical outcome. CONCLUSIONS: Current data support NLR as a prognostic biomarker in patients with advanced RCC receiving avelumab plus axitinib or sunitinib.
dc.formatPrint
dc.format.extent738 - 747
dc.languageeng
dc.language.isoeng
dc.publisherAMER ASSOC CANCER RESEARCH
dc.relation.ispartofClinical Cancer Research
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subjectAdult
dc.subjectAntibodies, Monoclonal, Humanized
dc.subjectAntineoplastic Combined Chemotherapy Protocols
dc.subjectAxitinib
dc.subjectCarcinoma, Renal Cell
dc.subjectHumans
dc.subjectKidney Neoplasms
dc.subjectLymphocytes
dc.subjectNeutrophils
dc.subjectRetrospective Studies
dc.subjectSunitinib
dc.titleAssociation of Neutrophil-to-Lymphocyte Ratio with Efficacy of First-Line Avelumab plus Axitinib vs. Sunitinib in Patients with Advanced Renal Cell Carcinoma Enrolled in the Phase 3 JAVELIN Renal 101 Trial.
dc.typeJournal Article
dcterms.dateAccepted2021-11-15
dc.date.updated2022-08-22T10:46:59Z
rioxxterms.versionVoR
rioxxterms.versionofrecord10.1158/1078-0432.CCR-21-1688
rioxxterms.licenseref.startdate2022-02-15
rioxxterms.typeJournal Article/Review
pubs.author-urlhttps://www.ncbi.nlm.nih.gov/pubmed/34789480
pubs.issue4
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Melanoma and Kidney Cancer
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Melanoma and Kidney Cancer/Melanoma and Kidney Cancer (hon.)
pubs.publication-statusPublished
pubs.volume28
dc.contributor.icrauthorLarkin, James
icr.provenanceDeposited by Mr Arek Surman on 2022-08-22. Deposit type is initial. No. of files: 1. Files: 738.pdf


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

https://creativecommons.org/licenses/by-nc-nd/4.0/
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by-nc-nd/4.0/